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Abstract
Background: The Me´decins Sans Frontie`res project of Uzbekistan has provided multidrug-resistant tuberculosis treatment
in the Karakalpakstan region since 2003. Rates of default from treatment have been high, despite psychosocial support,
increasing particularly since programme scale-up in 2007. We aimed to determine factors associated with default in multi-
and extensively drug-resistant tuberculosis patients who started treatment between 2003 and 2008 and thus had finished
approximately 2 years of treatment by the end of 2010.
Methods: A retrospective cohort analysis of multi- and extensively drug-resistant tuberculosis patients enrolled in treatment
between 2003 and 2008 compared baseline demographic characteristics and possible risk factors for default. Default was
defined as missing $60 consecutive days of treatment (all drugs). Data were routinely collected during treatment and
entered in a database. Potential risk factors for default were assessed in univariate analysis using chi-square test and in
multivariate analysis with logistic regression.
Results: 20% (142/710) of patients defaulted after a median of 6 months treatment (IQR 2.6–9.9). Factors associated with
default included severity of resistance patterns (pre-extensively drug-resistant/extensively drug-resistant tuberculosis
adjusted odds ratio 0.52, 95%CI: 0.31–0.86), previous default (2.38, 1.09–5.24) and age .45 years (1.77, 1.10–2.87). The
default rate was 14% (42/294) for patients enrolled 2003–2006 and 24% (100/416) for 2007–2008 enrolments (p = 0.001).
Conclusions: Default from treatment was high and increased with programme scale-up. It is essential to ensure scale-up of
treatment is accompanied with scale-up of staff and patient support. A successful first course of tuberculosis treatment is
important; patients who had previously defaulted were at increased risk of default and death. The protective effect of severe
resistance profiles suggests that understanding disease severity or fear may motivate against default. Targeted health
education and support for at-risk patients after 5 months of treatment when many begin to feel better may decrease
default.
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Introduction
Multidrug-resistant tuberculosis (MDR-TB) is defined as Myco-
bacterium tuberculosis resistant to at least isoniazid and rifampicin, the
two most effective anti-TB drugs. In 2011, an estimated 630,000 of
the world’s 12 million prevalent cases of TB were MDR, and an
estimated 310,000 (range 220,000–400,000) of these were among
notified TB patients with pulmonary TB [1,2]. The highest
proportions of MDR-TB are found in the countries of Eastern
Europe and Central Asia. In Uzbekistan a TB drug-resistance
survey completed in 2011 found that 23% of new and 62% of
previously treated TB patients had MDR-TB [1]. Uzbekistan is
one of the 27 WHO high-burden MDR-TB countries and was
recently ranked highest globally in terms of estimated incidence of
newly transmitted MDR-TB within the population [1,3]. Treat-
ment for MDR-TB uses second-line drugs that are less effective
than those used for first-line treatment and which often have
significant side-effects [4]. It is also lengthy, complex and
expensive [5]. As a result, treatment outcomes for patients with
MDR-TB are worse than for drug-sensitive TB, with low success
rates and high rates of treatment failure and default [4]. While
some analyses of MDR-TB treatment cohorts have reported
factors associated with negative outcomes of treatment (death,
failure and default) [6,7,8], it is not clear that the risk factors
associated with these three outcomes are necessarily the same.
Factors associated with default for drug-sensitive TB pro-
grammes are well described and include: individual patient profile
(e.g. illicit drug use), clinical status or therapy (e.g. side-effects of
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drugs) or health-service characteristics (e.g. distance of patients
from clinic or the way that patients are treated by staff) [9]. Factors
associated with default from MDR-TB have been less well
described.
Me´decins Sans Frontie`res (MSF), together with the Ministry of
Health, initiated a DOTS-plus project to treat MDR-TB in 2003
in Karakalpakstan, Uzbekistan. The initial programme model and
patients’ outcomes have been described [10]. By June 2011, 1796
patients with TB showing any form of drug resistance had been
enrolled in treatment in Karakalpakstan. Despite psychosocial
support being offered to patients, rates of default from treatment
have been relatively high, increasing particularly since 2007 when
the programme was scaled up. In a retrospective cohort analysis,
we aimed to determine factors associated with default in MDR
and extensively drug-resistant (XDR) TB patients who started
treatment between 2003 and 2008 and thus had the opportunity to
finish 2 years of treatment by the end of 2010.
Methods
Study Setting
The Republic of Karakalpakstan is a sovereign republic in the
north-west of the Republic of Uzbekistan. Although it covers
approximately one-third of the country of Uzbekistan, it contains
less than 6% of the population, around 1.6 million people. The
prevalence of TB in Karakalpakstan in 2009 was reported as 433/
100,000 population, considerably higher than in the rest of
Uzbekistan (227/100,000) [11,12]. From 2003, MSF in collabo-
ration with the Ministry of Health enrolled patients from Nukus
city and Chimbay district in a DOTS-plus programme.
Definitions
Registration groups based on patients’ treatment history were
assigned according to WHO standards; a patient with a TB
treatment history of more than 1 month at the time of sputum
submission was considered to be previously treated [13].
Treatment outcomes were defined according to WHO definitions,
and were determined by a medical team including Ministry of
Health and MSF doctors. Successful treatment outcomes included
‘‘cure’’ and ‘‘treatment complete’’. Default was defined as missing
at least 60 days of consecutive doses of all drugs. Pre-XDR TB was
defined as MDR-TB with resistance to an injectable anti-TB drug
(capreomycin or kanamycin) or a fluoroquinolone (ofloxacin), but
not both. XDR-TB was defined as MDR-TB with resistance to
both an injectable anti-TB drug (capreomycin or kanamycin) and
a fluoroquinolone.
Study Population and Programme Characteristics
Drug susceptibility testing (DST) was initially provided only for
patients with suspected drug-resistant TB, but was expanded to
include all smear-positive patients from 2006. A total of 830
patients with confirmed drug-resistant TB were started on
treatment between October 2003 and 31st December 2008 in
two districts of Karakalpakstan: 21 had mono-resistant (2.5%), 94
polydrug-resistant (11.5%), 710 MDR (85.5%) - 140 of whom
were pre-XDR - and four XDR (0.5%) TB. Analysis for this study
was restricted to 710 patients with MDR or XDR-TB, excluding
four patients who transferred in or out of the programme.
Programme characteristics from 2003–2005 have been described
[10]. All patients were hospitalised at the commencement of
treatment; as the programme scaled up, criteria for discharge were
altered to allow earlier discharge for ongoing ambulatory
treatment. Individualised treatment regimens were updated during
the study period to reflect updated international guidelines [13].
Health educators were replaced by psychosocial support counsel-
lors in 2007 with the aim of maximising adherence. Food was
provided in hospital, and monthly food packages were provided
for discharged patients. Financial support was provided for patient
transport to outpatient facilities (until 2009) and incentives were
paid to Ministry of Health doctors and nurses (until 2009).
Laboratory Testing
Sputum smear microscopy, culture and DST were conducted
according to international standards in the Nukus mycobacteriol-
ogy laboratory. Smears were assessed using Ziehl-Neelsen staining
or auramine fluorescence microscopy and culture using Low-
enstein-Jensen Media. DSTs were performed on Lowenstein-
Jensen cultures in the Nukus mycobacterial laboratory and
repeated at the supranational reference laboratory in Borstel,
Germany, for samples until April 2006, as previously described
[14]. Thereafter, external quality control tests of the Nukus
laboratory were evaluated by the Borstel laboratory and by
Gauting supranational reference laboratory in Germany from
2009. The Nukus mycobacterial laboratory was found to have
successfully passed the external quality assessment of drug
susceptibility testing each year to date. The BACTECTM
MGITTM 960 liquid culture system (BD, Franklin Lakes, NJ,
USA) was introduced to the laboratory for first-line drug testing in
September 2007. First-line DSTs were performed using the critical
concentration method in the BACTECTM MGITTM 960 system
using BACTECTM MGITTM 960 SIRE Kit and the BACTECTM
MGITTM 960 PZA Kit (BD, Franklin Lakes, NJ, USA). Drug
susceptibility testing for second-line antibiotics was performed on
Lowenstein-Jensen media by the proportion method.
Data Collection
Data were routinely collected from patient forms and registers
over the course of treatment and entered into a custom-made Epi-
Info project database (Epi-Info version 6, CDC, Atlanta, USA).
Data collected at baseline included demographics, prior history of
TB treatment, most recent DST results and regimen. Follow-up
data included adherence, outcome and laboratory results. Data
were exported into STATA (version 10.1, StataCorp LP, Texas,
USA) for analysis.
Statistical Analyses
A retrospective cohort analysis was performed on baseline
demographic characteristics and possible factors associated with
default in M/XDR TB patients enrolled for treatment between
2003 and 2008. Proportions were compared between defaulters
and successfully treated patients using the chi-square test for
demographic characteristics (sex, age, marital status) and possible
risk factors for default (unemployed, body-mass index [BMI]
,18 kg/m2, use of alcohol or tobacco, previous imprisonment,
previous travel outside region, previous TB treatment, previous
default from TB treatment and resistance profile at diagnosis).
Referent groups for resistance profile at diagnosis were as follows:
resistance to 2nd line drugs compared to resistance to 1st line drugs
only, pre-XDR/XDR compared to MDR with no fluorquinolone
or injectable resistance, resistant to $5 drugs compared to
resistant to ,5 drugs. Factors that were associated with default
in univariate analysis at p,0.10 were assessed in multivariate
analysis using a logistic regression model with stepwise forward
selection, including a variable for the time period (2007 or later)
when a number of programmatic characteristics changed as
treatment was scaled up. Likelihood ratio tests were conducted
after each stepwise addition to assess which variables to retain in
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the model. Similar regression analyses were performed for the
outcomes of death and failure.
The study met the standards set by the MSF Ethics Review
Board for retrospective analyses of routinely collected program-
matic data.
Results
Among 710 M/XDR-TB patients enrolled in the DOTS-plus
programme between 2003 and 2008:62% (438) were successfully
treated according to WHO definitions, 20% (142) defaulted from
treatment, 7% (50) died and 11% (80) failed treatment. The
median age of patients was 29.4 years (IQR 23.1–40.3) and 48%
(343) were male. The length of time patients were hospitalised
decreased in 2007 to a median of 3.7 months and 3.4 months in
2008, compared to 5.0–9.5 months in each of the previous 4 years.
The median overall time on treatment was 20 months. Possible
risk factors were assessed for patients who were successfully treated
compared with those who defaulted from treatment. For patients
enrolled between 2003 and 2006 the proportion who defaulted
was 14.3% (42/294); this increased significantly to 24% (100/416)
for patients enrolled in 2007 and 2008 (p = 0.001). The median
time to last dose of drugs taken by defaulters was 6.1 months from
the start of treatment (IQR 2.6–9.9), with 59.9% (85/142)
defaulting in the ambulatory phase of treatment. While approx-
imately 25% of defaulters took their last dose in autumn or
summer, fewer did so in winter (20/142, 14%, p,0.001) and more
did so in spring (48/142, 34%, p= 0.03).
Factors associated with default from treatment (univariate
analysis) included patients who were 45 years or older, had
previously travelled outside the region, or had previously defaulted
from treatment. Protective factors for default included previous
failure of category II treatment (defined as an 8-month retreatment
regimen with first-line drugs), previous treatment with second-line
drugs and a more severe resistance profile (ie pre-XDR/XDR
resistance) at diagnosis (Table 1).
After adjustment through multivariate analysis, patients with
more severe resistance patterns were protected from default (pre-
XDR/XDR compared to less resistance (MDR with no fluoro-
quinolone or injectable resistance) adjusted odds ratio
[aOR]= 0.52; 95% CI 0.31–0.86; p = 0.011), while patients who
had previously defaulted from treatment (aOR=2.38; 95% CI
1.09–5.24; p = 0.030), older patients (aOR=1.77; 95% CI 1.10–
2.87; p = 0.020) and those whose treatment started in 2007 or
2008 (aOR=1.70; 95% CI 1.10–2.73; p = 0.030) were more likely
to default (Table 2).
Factors associated with death in multivariate analysis were low
BMI (,18 kg/m2) at admission (aOR=3.5; 95% CI 1.7–7.3;
p = 0.001), more than one cavity at diagnosis (aOR=3.4; 95% CI
1.3–9.1; p = 0.014) and treatment after default from previous
treatment (aOR=3.0; 95% CI 1.2–7.6; p = 0.020). No factors
associated with treatment failure on univariate analysis remained
significant after adjustment for co-factors in multivariate analysis.
Discussion
The main factors associated with default in our cohort after
adjustment in multivariate analysis were age (.45 years), previous
default from tuberculosis treatment and less severe DST profile at
diagnosis. In a retrospective analysis of a cohort in Latvia, no
identified factors were found to be significantly associated with
default from MDR-TB treatment [8]. An analysis of patients
treated in MDR-TB programmes in Estonia, Latvia, Philippines,
Russia and Peru between 2000–2004 reported primarily socio-
economic factors as predictors for default, but did not discuss
whether this varied by country [15]. Factors identified in other
countries as associated with default included alcohol or drug use
[16,17], substandard housing, increased number of drugs for
treatment, centralised treatment [18], homelessness, unemploy-
ment, history of imprisonment, and baseline positive smear result
[15]. Our results thus highlight the need for MDR-TB
programmes to identify local risk factors for default.
As the programme was scaled up, default rates rose in our
cohort from 14% to 24%, concurrent with increased patient
numbers. Our rates are not atypical; a meta-analysis of over 9000
patients reported an overall default rate of 23% [19]. Such high
rates show the urgent need to better understand predictive factors
for default from MDR-TB treatment.
In contrast to default from treatment, factors associated with
death were largely related to severity of disease at initiation of
treatment. The association between default and re-treatment after
previously defaulting (aOR 2.38) shows the importance of success
with the first regimen of TB treatment offered to a patient. Patients
who had previously defaulted were at increased risk of not only
subsequent default, but also of death. Previously treated patients
should have additional support at the start of a new treatment to
emphasise the importance of adherence and completion. Before
starting a new course of treatment, patients who previously
defaulted need special attention to ascertain and address the issues
that contributed to them defaulting.
Interestingly, patients with more severe resistance profiles (pre-
XDR/XDR) were less likely to default, perhaps indicating that an
understanding of the severity of disease or fear were motivations to
persevere with treatment. This finding contrasts with an analysis of
patients in the Philippines, who were at increased risk of default
with increasing numbers of drugs in their regimen [18]. We
hypothesise that many patients with less severe resistance profiles
feel better after 6 months of treatment and may believe they are
cured, reducing the perceived value of continuing treatment,
whereas patients with more severe resistance profiles may be more
aware of the gravity of their disease and thus are less likely to
default. More exploration of these hypotheses is needed and
qualitative interviews are planned. Targeted health education of
these patients after 5 months of treatment, when many patients
have begun to feel better, may decrease default from treatment.
As the programme was scaled up, default rates increased.
During the period of analysis, programmatic changes were made
in order to scale-up access to drug-resistant TB diagnosis and
treatment, resulting in about 200 patients with drug-resistant TB
starting treatment annually from 2007 onwards. These changes
included an increase in the ratio of patients starting treatment per
doctor/nurse treating, a decrease in the length of hospitalisation, a
decrease in the size of food packages given to patients in
ambulatory treatment, a change in drug regimen (initial treatment
changed from ethionamide to prothionamide), and a change in
patient profile (more patients without previous TB treatment were
included in later years). These factors have not been included in
our review of baseline factors as they aligned too closely with the
period before and after scale-up, and thus their potential role can
only be hypothesised. Similar results to ours were found in a meta-
analysis of default in drug-resistant TB with rates tending to
increase with treatment cohort size [20]. If the WHO policy to
scale-up to universal access for drug-resistant TB diagnosis and
treatment [2] is to be successful, it is essential to ensure that scale-
up of patient numbers is matched by scale-up of staff, decentralis-
ing patient treatment in order to spread patient burden across sites
and increasing patient support.
While many factors contribute to default from MDR-TB
treatment, our results suggest that overall TB treatment outcomes
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could be improved with strengthened education during the first
TB treatment, and targeted educational and psychosocial support
to those at greatest risk of default from MDR-TB treatment. These
interventions should support patients in the challenges they face,
help them understand the severity of the disease and motivate by
emphasising both the value of treatment availability and the risks
of defaulting from treatment.
Further work is required to investigate the reasons why the
factors we identified are associated with increased risk of default
and how they can be addressed. The limitations of our study
include lack of testing for susceptibility to amikacin, meaning that
some pre-XDR or XDR patients may have been misclassified as
MDR. However, cross-resistance between kanamycin and amika-
cin is high in the programme region [21] so misclassification is
unlikely to have affected many patients. Other limitations include
that the study analysed retrospective data and that we reviewed
only baseline factors, which mean that we could not assess the
effects of changes in the programme over time or other factors
which could influence default such as patient, treatment and
service factors. The strengths of the study include the large cohort
size and thus the large number of defaulters available for analysis.
Default rates from MDR-TB treatment are known to be high
and defaulters have an increased risk of mortality, resistance
amplification and transmission of resistant TB within the
community. It is important for programmes to identify local risk
factors for default and for further research to demonstrate the best
programme models for reducing default. Current ambitions to
achieve universal access to treatment for drug-resistant TB [2] will
fail to curb the spread of disease if default rates are not addressed.
Table 1. Baseline proportions and association of factors with default by univariate analysis.
Success N (%) Default N (%) p
Total patients unless otherwise stated 438 142
Demographic
characteristics
Sex (male) 207 (47.3) 79 (55.6) 0.083
Age (.45 years) 68 (15.5) 34 (23.9) 0.022
BMI ,18 kg/m2 202 (46.0) 70 (49.3) 0.510
Married 223 (50.9) 68 (47.9) 0.531
Unemployed 211 (48.2) 74 (52.1) 0.415
Potential high
risk groups
Tobacco use 55 (12.6) 21 (14.8) 0.493
Alcohol use 63 (14.4) 27 (19.0) 0.185
Prisoner (at/prior to admission) 22 (5.0) 12 (8.5) 0.131
Travel outside Karakalpakstan 71 (16.2) 35 (24.7) 0.024
MDR Contact 27 (6.2) 8 (5.6) 0.818
Registration group/
Previous TB treatment
New 74 (16.9) 20 (14.10) 0.430
Relapse 124 (28.3) 47 (33.1) 0.277
Treatment after default 20 (4.6) 13 (9.2) 0.040
Treatment after failing cat I 32 (7.3) 13 (9.2) 0.474
Treatment after failing cat II 119 (27.2) 25 (17.6) 0.022
Other 69 (15.8) 24 (16.9) 0.746
Previous second-line treatment 171 (39.0) 42 (29.6) 0.042
Resistance profile
at diagnosis
Resistant to second-line drugs
(compared to first-line drugs only)
153/437 (35.0) 43/142 (30.3) 0.301
Pre-XDR/XDR (compared to MDR with no
fluoroquinolone or injectable resistance)
117/437 (26.7) 23/142 (16.2) 0.011
Resistant to $5 drugs (compared to
resistant to ,5 drugs)
192/437 (43.9) 54/142 (38.0) 0.216
BMI = body-mass index. MDR =multidrug-resistant. Cat I = category I treatment. Cat II = category II treatment. XDR = extensively drug-resistant.
doi:10.1371/journal.pone.0078364.t001
Table 2. Factors associated with default identified by
multivariate analysis.
Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
Pre-XDR/XDR 0.53 (0.32–0.87) 0.011 0.52 (0.31–0.86) 0.011
Age (.45 years) 1.71 (1.07–2.73) 0.022 1.77 (1.10–2.87) 0.020
Treatment
after default
2.10 (1.02–4.37) 0.040 2.38 (1.09–5.24) 0.030
Time period
(2007 or later)
1.71 (1.13–2.58) 0.010 1.70 (1.10–2.73) 0.030
Treatment after
failing cat II
0.57 (0.35–0.93) 0.022 0.85 (0.49–1.49) 0.585
Travel outside
Karakalpakstan
1.69 (1.07–2.68) 0.023 1.43 (0.87–2.35) 0.157
Sex (male) 1.40 (0.96–2.05) 0.083 1.25 (0.83–1.89) 0.278
OR=odds ratio. XDR = extensively drug-resistant. Cat II = category II treatment.
doi:10.1371/journal.pone.0078364.t002
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